Head-to-head · free

NeoGenomics, Inc. vs National HealthCare Corporation

NEO vs NHC — return on capital, cash generation, margins and balance sheet side by side.

NEO

0 / 2

measures where NEO leads

NHC

2 / 2

measures where NHC leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureNEO · FY2025NHC · FY2025
Revenue—$1.5B
Net income(108.0M)$120.0M
Revenue growth (yearly, multi-year)—9.0%
Free cash flow(21.8M)$148.6M
Free cash flow margin—9.8%
Net cash / (debt)——
ROIC——
Return on equity-12.4%—
Gross margin43.2%—
Operating margin-12.1%—
Net debt / EBITDA-3.79x—

Figures are as reported by each company; latest fiscal year shown.

Where NeoGenomics, Inc.'s cash went (FY2025)

Capital spending
$27.0M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full NEO profile →

Where National HealthCare Corporation's cash went (FY2025)

Capital spending
$36.4M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full NHC profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons